FutraMed, Inc. is a medical technology company addressing the opioid crisis with the Limoge TCES—a non-invasive, handheld neuromodulation device designed to manage Opioid Use Disorder (OUD) across both acute and long-term phases. Backed by prior European regulatory approval and built for ease of use in clinical or rural settings, the Limoge TCES safely alleviates withdrawal symptoms and supports sustained recovery by enhancing neuroplasticity and emotional resilience. We are currently pursuing FDA clearance and seeking strategic partners and early investors to help bring this transformative technology to detox centers, rehab programs, and underserved communities across the U.S.

FutraMed, Inc.

Org chart

Teams

Offices